Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Prognostic stratification of ulcerated melanoma: not only the extent matters

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neutrophils contain cholesterol crystals in transfusion-related acute lung injury (TRALI)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers.

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: This study presents the clinical assessment of the Onclarity HPV Assay (Becton Dickinson) on the novel COR high-throughput instrument (Becton Dickinson) using the international guidelines in a routine setting.

METHODS: Screening samples collected in BD SurePath from women aged 30 years and older were used in this validation. Noninferiority of the Onclarity HPV Assay on the COR instrument (Onclarity-COR) was assessed with the comparator assay glycoprotein 5-positive (GP5+)/6+ enzyme immunoassay (GP-EIA) for clinical sensitivity on 122 cervical intraepithelial neoplasia 2 and greater samples. Specificity was assessed using 887 samples with twice-normal cytology. Inter- and intralaboratory reproducibility analysis was assessed using 525 samples. Finally, a time-and-motion study was performed to evaluate COR instrument performance characteristics.

RESULTS: The Onclarity-COR was noninferior to the GP-EIA for both sensitivity (P = .0016) and specificity (P < .0001). The intralaboratory reproducibility was 98.3% (κ = 0.96), and interlaboratory agreement was 98.5 % (κ = 0.96). The daily hands-on time for the COR instrument was 58 minutes, and walk-away time was 7 hours, 2 minutes per 8-hour day shift.

CONCLUSIONS: The Onclarity-COR instrument fulfills international validation criteria on sensitivity, specificity, and laboratory reproducibility. The Onclarity assay's extended genotyping capability, together with its high-throughput characteristics, makes the COR instrument an excellent candidate for use in human papillomavirus primary cervical cancer screening.

Original languageEnglish
JournalAmerican Journal of Clinical Pathology
ISSN0002-9173
DOIs
Publication statusE-pub ahead of print - 21 Sep 2021

Bibliographical note

© American Society for Clinical Pathology, 2021.

ID: 67900865